Cancer genomic studies that rely on analysis of biopsies from primary tumors may not fully identify the molecular events associated with tumor progression. We hypothesized that characterizing the transcriptome during tumor progression in the TH-MYCN transgenic model would identify oncogenic drivers that would be targetable therapeutically. We quantified expression of 32,381 murine genes in nine hyperplastic ganglia harvested at three time points and four tumor cohorts of progressively larger size in mice homozygous for the TH-MYCN transgene. We found 93 genes that showed a linearly increasing or decreasing pattern of expression from the preneoplastic ganglia to end stage tumors. Cross-species integration identified 24 genes that were highly expressed in human MYCN-amplified neuroblastomas. The genes prioritized were not exclusively driven by increasing Myc transactivation or proliferative rate. We prioritized three targets [centromere-associated protein E (Cenpe), Gpr49, and inosine monophosphate dehydrogenase type II] with previously determined roles in cancer. Using siRNA knockdown in human neuroblastoma cell lines, we further prioritized CENPE due to inhibition of cellular proliferation. Targeting CENPE with the small molecular inhibitor GSK923295 showed inhibition of in vitro proliferation of 19 neuroblastoma cell lines (median IC 50 , 41 nmol/L; range, 27-266 nmol/L) and delayed tumor growth in three xenograft models (P values ranged from P < 0.0001 to P = 0.018). We provide preclinical validation that serial transcriptome analysis of a transgenic mouse model followed by cross-species integration is a useful method to identify therapeutic targets and identify CENPE as a novel therapeutic candidate in neuroblastoma.
Introduction
Neuroblastoma is a pediatric cancer that arises from the developing sympathetic nervous system. Forty percent of cases present with a "high-risk" phenotype characterized by wide dissemination at diagnosis, unfavorable biology, and a high risk of relapse and treatment failure (1) . Despite intensification of chemoradiotherapy, high-risk tumors historically have overall survival under 40% (2, 3) . Further intensification risks adding negligible benefit at a significant cost (4, 5) . A phase III trial targeting the ganglioside GD2 glycolipid, with chimeric monoclonal antibody (ch14.18) and cytokines, recently reported the first substantive improvement in survival by reducing relapse by 20% in high-risk disease (6) . This suggests that incorporation of targeted therapeutics may improve treatment outcomes for children with high-risk neuroblastoma.
High-risk neuroblastomas acquire copy number aberrations that are distinct from low-and intermediate-risk cases, suggesting regions of recurrent somatic alterations harbor candidate genes (7) (8) (9) (10) . The seminal example of this is MYCN oncogene amplification, which is highly predictive for adverse outcome (11, 12) , but MYCN is not yet pharmacologically tractable. An ongoing genome-wide association study has identified multiple single-nucleotide polymorphisms (13, 14) and copy number variations (15) associated with sporadic neuroblastoma. Total attributable risk from these loci remains modest. Genome-wide linkage analysis of familial neuroblastoma pedigrees identified germline mutations in anaplastic lymphoma kinase (ALK) as the major familial neuroblastoma predisposition gene (16) . Whereas inhibition of ALK is a highly attractive therapeutic target for this subset of patients, tractable molecular targets have not been identified for the majority of high-risk patients.
Here, we use a transgenic model of high-risk neuroblastoma to discover somatic transcriptional alterations in murine tumors that seem to be critical for progression. By filtering this list with both human neuroblastoma transcriptional data and matching the resultant gene list with anticancer drugs currently in development, we show the utility of this strategy in the prioritization of early-phase clinical trial planning.
Materials and Methods
Homozygous TH-MYCN +/+ mice. TH-MYCN mice bred to homozygosity (TH-MYCN +/+ ) develop tumors with near complete penetrance (17) (18) (19) . TH-MYCN +/+ mice were sacrificed at birth, day 7, or day 14 to harvest superior cervical and celiac sympathetic ganglia. Ultrasonography (Vevo770 Visual Sonics) was performed thrice per week. Mice were sacrificed when tumors were within one of four predetermined size ranges (six mice per cohort). Specimens were cryopreserved for nucleic acid extraction or preserved in paraffin and ornithine carbamyl transferase for histologic evaluation. Mice were maintained under the protocols and conditions were approved by the Institutional Animal Care and Use Committee.
Immunohistochemistry. We stained with endothelial cell marker CD34 (Abcam, ab8158, Cambridge, MA) at 1:50 dilution to quantify vessels. Sections were incubated with a biotinylated goat anti-mouse secondary antibody, and tertiary staining was with horseradish peroxidase-conjugated streptavidin. The immune complex was visualized by using liquid 3,3′-diaminobenzidine as a chromagen (DAKO, LSAB 2 System, K0673, North American, Inc.).
Microarray. RNA was extracted from 10-μm frozen sections using Qiagen RNeasy Micro kit (Qiagen). Tumor total RNA (76 ng to 1.6 μg) was used to generate cDNA targets that were hybridized to the Applied Biosystems Mouse Genome Survey Microarray version 1.0, and ganglia samples (which became available later in the experimental plan) were hybridized to version 2.0 of the array. Two tumors were hybridized to both microarray versions for quality control. All microarray data are available at the National Center for Biotechnology Information (NCBI) web site (http://www.ncbi.nlm.nih.gov/ geo/query/acc.cgi?acc=GSE17740).
Differential expression in ganglia and tumor progression. We analyzed tumor and ganglia data sets separately, as they were analyzed on different microarray versions, and ganglia specimens required additional genome amplification before hybridization. Transcripts were excluded (a) if they were not present on both microarray versions, (b) if they had no human orthologues, or (c) if transcripts were not expressed in at least three tumor specimens within any cohort. To identify genes with serially increasing or decreasing expression across the ganglia and tumor samples, we calculated nonparametric Spearman's correlation coefficients for each transcript. We used a permutation test to evaluate the false discovery rate of identified genes.
Cross-species integration. We carried out cross-species integration to identify transcripts that were overexpressed with murine neuroblastoma progression and human highrisk MYCN-amplified neuroblastomas. We tested human gene expression by comparing 28 low-risk and 20 MYCN-amplified high-risk neuroblastoma transcriptomes, previously assayed using the Human Genome U95v2 expression microarray platform (http://www.ncbi.nlm.nih. gov/geo/query/acc.cgi?acc=GSE3960) (20) . The murine genes were mapped to Affymetrix U95 probe sets using the NCBI Homologene database. Genes with concordant overexpression in murine and human neuroblastomas proceeded to manual curation prioritizing druggable targets based on literature review. PANTHER classification system was used to classify biological function of genes with concordant expression (21) .
Quantitative reverse transcription-PCR. Real-time quantitative reverse transcription-PCR (RT-PCR) was performed on TH-MYCN +/+ tumors (Applied Biosystems). Relative expression of target genes was determined by normalization to β-2-microglobulin, TATA box binding protein, and hypoxanthine phosphoribosyltransferase using a standard curve. All experiments were performed in triplicate.
MYC transcriptional activity during tumor progression. We evaluated expression of the murine Mycn and Mycc and human MYCN during tumor progression using quantitative RT-PCR. We quantified Myc transcriptional activity using a clinically validated a priori defined gene expression signature (22) based on the Myc target gene database (http://www. myccancergene.org/index.asp) (23) . High Myc transcriptional activity was indicated by upregulation or downregulation of Mycc, Mycn, and Mycl target genes.
siRNA validation. Functional validation of manually curated genes in a human neuroblastoma-derived cell line (NB1643) was performed using transient transfection of siRNA against tumor-associated calcium signal transducer-1 (TACSTD1), inosine monophosphate dehydrogenase type II (IMPDH2), GPR49, and centromere-associated protein E (CENPE; Dharmacon, Thermo Scientific). CENPE siRNA knockdown was also performed in NB-EBc1, Kelly, SKNAS, and NGP. Cell proliferation was monitored using the RT-CES (ACEA Biosciences), which measures substrate adherent growth in real time, as described previously (24) . Each experiment was performed in triplicate.
Cell cycle analyses. Cells were seeded at 50% confluence and cultured overnight to allow cell attachment. Cells were treated with inhibitor 24 h after seeding. At each treatment, time point media were removed and cells were harvested using 0.05% Trypsin-EDTA. Media and trypsin fractions were then combined and spun. Cells were fixed with ice-cold ethanol overnight. Membranes were permeabilized by incubating in phosphate-citric acid buffer for 5 min. Cells were spun and incubated with propidium iodide (50 μg/mL) and RNase A (250 μg/mL) for 30 min and analyzed by flow cytometry using a FACSCalibur (BD Bioscience).
Pharmacologic CENPE inhibition. In vitro activity of GSK923295 dissolved in DMSO was evaluated in 19 neuroblastoma cell lines using the RT-CES system. IC 50 was calculated from the area under the curve across a four-log dose range (1-10,000 nmol/L).
Xenograft studies. CB17 scid mice (Taconic Farms) were used to propagate s.c. implanted neuroblastoma tumors. Tumor diameters were measured using calipers. Tumor volumes were calculated using the formula, (π/6) * diameter 3 . Once tumor volume exceeded 200 mm 3 , mice were randomized (n = 10 per arm) to receive either 125 mg/kg i.p.
GSK923295 or vehicle (96% acidified water, 2% DMAC, 2% CREM) for a total of six doses using a 3 d on-4 d off-3 d on regimen.
Proliferative signature during tumor progression. We used an a priori-defined "proliferative signature" that identified genes that are upregulated in rapidly proliferating cells, both malignant and nonmalignant (25) . We compared the distribution of nonparametric Spearman's correlation coefficients of the "proliferative signature" transcripts to murine transcripts with human orthologues that were not contained within the proliferative signature.
Results
Modeling tumor progression. We sacrificed TH-MYCN +/+ mice at day 0 (n = 5), day 7 (n = 2), and day 14 (n = 2) of life to harvest sympathetic ganglia containing foci of neuroblast hyperplasia. To model progression of macroscopic tumors, we monitored tumor growth in TH-MYCN +/+ mice using ultrasound. Mice were sacrificed when tumor dimensions were within predetermined ranges (Fig. 1 ).
Increasing tumor volume on ultrasound corresponded to increasing tumor weight: group A, mean weight 0.08 ± 0.02 g; group B, 0.35 ± 0.09 g; group C, 0.94 ± 0.22 g; and group D, 2.01 ± 0.59 g. We confirmed that harvesting tumors at different sizes provides a model of neuroblastoma progression by comparing cohorts for macroscopic and histologic vascularity, locoregional invasion, infiltration of intratumoral vasculature, and metastases. The smallest tumors were asymptomatic and avascular and had no evidence of metastasis. With increasing tumor size, there was increasing displacement and invasion of local structures and increasing vascularity (Fig. 1A-D) . The two larger tumor sizes (groups C and D) invaded tumor vasculature, Figure 2 . A, algorithm for identifying 24 candidates from ∼32,000 transcripts. Transcripts showing a continuous increase or decrease in expression at clinically relevant stages of tumor progression and in hyperplastic ganglia at days 0, 7, and 14 were identified using Spearman's method. Microscopic ganglia required an additional round of amplification, so they were analyzed separately. Of the 93 transcripts, cross-species integration was used to prioritize 24 biologically important genes that were overexpressed in human high-risk MYCN-amplified neuroblastomas. B, heat map representation of 93 differentially expressed murine genes. Samples are grouped into ganglion samples (days 0, 7, and 14) and tumor samples (groups A-D) along the X axis. The 93 murine transcripts showing the most significant differential expression are shown along the Y axis, with red indicating greater expression and green indicating less expression. Four genes selected for functional evaluation are indicated. Note that murine Mycc and Mycn showed decreased expression with tumor progression. The full 93 gene set is described in Supplementary Table S2. and in the largest tumors (group D), distant metastases were detected (Supplementary Table S1 ).
Identification of differentially expressed genes associated with neuroblastoma progression. We assayed each harvested sample with a murine-specific microarray. Our algorithmic approach is shown in Fig. 2A . The murine-specific microarray interrogated 32,381 genes, of which 18,251 genes had human orthologues. The exclusion of transcripts with low expression in any tumor cohort yielded 11,320 transcripts for further consideration. We next identified transcripts showing the strongest correlation of mRNA quantity to tumor progression using Spearman's method (Supplementary Table S2 ). Using a conservative false discovery rate of 0.05, we obtained 1,127 transcripts. We filtered the 1,127 candidates by determining which transcripts showed the same direction of expression in murine sympathetic ganglia across day 0, day 7, and day 14 of life. Of 1,127 candidates, 93 transcripts showed a consistent alteration in mRNA quantity (one-tailed P ≤ 0.01) with progression from hyperplastic ganglia to advanced neuroblastomas ( Fig. 2B ; Supplementary Table S2) .
Cross-species integration of gene expression. Of the 93 murine genes with differential expression, 56 had homologues present on the human microarray platform and 32 of these had increasing expression with tumor progression. We focused on genes with increasing expression, as potential oncogenes provide a more tractable therapeutic target than potential tumor suppressors. Of the 32 murine transcripts, we found 24 unique genes that were overexpressed in human high-risk MYCN-amplified neuroblastoma compared with low-risk nonamplified neuroblastomas (Supplementary Table S2 ). The 24 genes with concordant overexpression in murine and human MYCN-amplified neuroblastoma were classified using PANTHER biological function (21) .
Manual curation of the 24 differentially expressed transcripts prioritized three genes with previously described roles in cancer and potential for therapeutic inhibition (Gpr49, Impdh2, and Cenpe). To act as a control for cross-species integration, we identified the transcript with the largest increase in expression across murine tumor progression that was not overexpressed in human MYCN-amplified neuroblastomas. This transcript was Tacstd1 gene. Quantitative PCR was used to confirm that the three candidate transcripts and the control transcript had increased expression with tumor progression (Fig. 3A-D) .
MYCN transactivation did not increase with tumor progression. To ensure that our candidate genes were not simply the result of the basal myc activity, we investigated whether the human MYCN transgene was driving alterations in gene expression with tumor progression. Human MYCN transgene expression increased with tumor progression, but murine Mycn and Myc showed a decrease in expression. Overall, the average expression of MYCN, Mycc, and Mycn remained unchanged from small avascular tumors to large metastasizing tumors (Fig. 4A) . Myc transcriptional activity, as indicated by upregulation or downregulation of Myc, Mycn, and Myc target genes, did not show a significant increase with tumor progression (Fig. 4B) . Cenpe, Gpr49, and Impdh2 showed a significant linear increase in expression with tumor progression (Fig. 3A-D) , but Myc transcriptional activity did not (Fig. 4B) .
Transcripts with increased expression were not exclusively composed of genes involved in proliferation. Following prioritization of the mitotic kinesin Cenpe, we sought to characterize if there was an excessive prevalence of other genes with cell cycle-related functions that were overexpressed in the larger murine tumors. Using an a prioridefined gene expression signature, we established that genes identified as being upregulated in rapidly dividing cells (25) were more likely to show upregulation in larger tumors compared with ∼18,000 other murine transcripts ( Supplementary  Fig. S1 ). Among the 93 murine transcripts showing the greatest differential expression with tumor progression, there were 49 wherein expression increased with tumor progression. Of the 49 murine transcripts showing the greatest increase in expression with tumor progression, only four were directly involved with DNA replication, two were in the kinetochore, and two were involved with purine synthesis.
Transcription of MYC target genes did not increase with tumor progression. To ensure that our candidate genes were not simply the result of the basal myc activity, we investigated whether the human MYCN transgene was driving alterations in gene expression with tumor progression. Human MYCN transgene expression increased with tumor progression, but murine Mycn and Myc showed a parallel decrease in expression. Overall, the average expression of MYCN, Mycc, and Mycn remained unchanged from small avascular tumors to large metastasizing tumors (Fig. 4A) .
To evaluate expression of Myc target genes in murine tumors, we used a predefined gene expression signature of Myc transcriptional targets shown to predict relapse and death from low-, intermediate-, and high-risk human neuroblastoma. This signature quantifies the overall pattern of transcription of Myc targets rather than limiting the evaluation to single transcripts. Overall transcription of the Myc target gene signature did not show a significant increase with tumor progression (Fig. 4B) .
Functional validation prioritizes CENPE for further investigation. To functionally validate and prioritize the three candidate neuroblastoma targets (CENPE, GPR49, and IMPDH2), we performed siRNA knockdown in a MYCN-amplified human neuroblastoma-derived cell line (NB-1643). We also knocked down the control gene (TACSTD1), which was overexpressed with tumor progression but not overexpressed by human highrisk MYCN-amplified neuroblastomas. siRNA knockdown resulted in variable effects on cellular proliferation. Transient knockdown of TACSTD1 resulted in no significant decrease in growth velocity when compared with a targeted control, glyceraldehyde-3-phosphate dehydrogenase (GAPDH; Fig. 5A ). Knockdown of GRP49 (Fig. 5B) and IMPDH2 (Fig. 5C ) showed modest inhibition of proliferation, but knockdown of CENPE resulted in the greatest inhibition prioritizing CENPE for further evaluation (Fig. 5D) . Finally, to assure that the CENPE siRNA inhibition was not specific to the human neuroblastoma cell line NB1643, we performed additional transient siRNA knockdown experiments in three additional MCYN-amplified human neuroblastoma-derived cell lines (Kelly, NGP, and NBEbC1) as well as one nonamplified line (SKNAS). There was significant inhibition of cell growth in all three amplified lines, whereas the nonamplified line showed little effect ( Supplementary Fig. S2C ).
CENPE knockdown-induced suppression of neuroblastoma cell proliferation results from mitotic arrest. Following confirmation of knockdown by RT-PCR ( Supplementary  Fig. S2B ), we examined cell cycle inhibition in two human neuroblastoma cell lines (SKNAS and NGP) using flow cytometry. At 24 hours, there was an accumulating cell population in the G 2 -M phase of the cell cycle. Notably, there is no sub-2N population to suggest apoptotic cell death (Supplementary Fig. S2A ).
Pharmacologic inhibition of Cenpe results in antitumor activity in vitro and in vivo. We sought validation that pharmacologic CENPE inhibition was efficacious in preclinical models. A potent CENPE Inhibitor, GSK923295, showed broad efficacy against a panel of 19 human neuroblastoma-derived cell lines with an average growth IC 50 of 41 nmol/L (range, 27-266 nmol/L; Supplementary Table S3) . Growth IC 50 did not correlate to cell line MYCN amplification status (P = 0.51), CENPE copy number gain (P = 0.29), in vitro cell line doubling time (r = 0.41, P = 0.0805), or CENPE mRNA expression as previously assayed by the Illumina Human-6 v2 expression BeadChip (r = −0.12, P = 0.62). We selected three cell lines with a spectrum of in vitro growth IC 50 (NB-EBc1, 34 nmol/L; NB1643, 57 nmol/L; NB1691, 103 nmol/L) to assess in vivo GSK293295 activity. Xenografts of mice treated with GSK293295A showed significant tumor growth delay compared with the control arm (NB-EBc1, P < 0.0001; NB-1643, P = 0.018; NB-1691, P = 0.0018; Fig. 6 ). GSK293295A does not target murine Cenpe so no toxicity was seen, and a therapeutic index could not be estimated.
Discussion
Emerging evidence suggests that neuroblastoma initiation and progression occur due to a combination of inherited variants and mutations (13) (14) (15) (16) and stepwise somatic accumulation of drivers (10, 26) . Diagnostic specimens provide a snapshot at one time point and the molecular events associated with tumor evolution may not be fully identified. We hypothesized that characterizing the evolution of the neuroblastoma transcriptome at multiple time points would augment existing cancer gene discovery. We serially sacrificed TH-MYCN mice to obtain specimens to provide a model of human neuroblastoma progression. Using a transgenic system meant we could use cross-species integration to reduce the number of candidate genes before manual curation. Mouse tumors with chromosomal instability acquire genomic aberrations that are orthologous with their respective human cancers, suggesting that selection pressures are tissue specific Figure 5 . siRNA knockdown prioritizes CENPE for further functional evaluation. We monitored proliferation of NB-1643, a MYCN-amplified human neuroblastoma cell line, using the RT-CES microelectronic cell sensor system. A, the control gene TACSTD1, which was not overexpressed in human MYCN-amplified neuroblastomas, showed minimal inhibition of proliferation with knockdown. Inhibition was modest for GPR49 (B) and IMPDH2 (C). D, CENPE siRNA caused the greatest inhibition. The gene of interest is red, and GAPDH (negative control) is blue. All experiments performed in triplicate. Points, mean; bars, SEM. PLK (positive control) showed 100% cell kill at 72 h posttransfection in all cases. Figure 6 . Pharmacologic CENPE inhibition caused tumor growth delay in three human neuroblastoma xenografts. Mice were randomized to receive either 125 mg/kg i.p. GSK923295 (red) or vehicle (blue; 96% acidified water, 2% DMAC, and 2% CREM). Relative tumor volume (RTV) is the measured tumor volume divided by the enrollment tumor volume displayed as mean ± SEM. Linear mixed effects analysis showed smaller relative tumor volume in the treatment arm in all three xenografts. A, NB-EBc1, P = 0.0001; B, NB-1643, P = 0.018; and C, NB-1691, P = 0.0018. (27) . Cross-species integration has been used with the transcriptome, as expression signatures of oncogenic KRAS2 mutations were identified using cross-species integration transgenic and human cancers (28) . We predicted that biologically relevant alterations in gene expression would also be conserved. By identifying commonalities in gene expression, we posited that we would be more likely to identify critical driver genes that could be inhibited therapeutically.
MYCN overexpression is responsible for tumor initiation in the TH-MYCN model, but it was unknown whether increasing MYCN transcriptional activity accounted for differential gene expression with tumor progression. Overall expression of Myc homologues and Myc transcriptional activity remained constant with tumor progression, suggesting that increasing MYCN transactivation was not exclusively driving alterations in gene expression. These findings are consistent with the hypothesis that the latent period before murine neuroblastoma initiation is due to the time needed to acquire cooperating mutations (17) , which may contribute to differential gene expression. Following prioritization of the mitotic protein CENPE, we queried how many other genes identified had cell cycle-related functions. We established that genes upregulated in rapidly proliferating cells (25) showed greater upregulation with tumor progression than ∼18,000 other murine transcripts. However, of the 93 murine genes with the greatest differential expression, 49 of those had increasing expression, and of those only four were directly involved with DNA replication, two were in the kinetochore, and two were involved with purine synthesis. Therefore, upregulation of the remaining transcripts was not a direct result of increased proliferative rate. These validations increase our confidence that we have not purely identified candidate genes that are artifacts of the model system but additional important functional mediators of tumorigenesis.
We identified 93 genes whose expression continuously increased or decreased across ganglia and tumor progression ( Fig. 1; Supplementary Table S2 ). We used cross-species integration to reduce the number of transcript candidates by selecting those genes whose expression was greater in high-risk MYCN-amplified neuroblastomas relative to low-risk tumors without amplification of MYCN (Supplementary Table S2 ). The resultant 24 genes were prioritized based on whether we could inhibit them pharmacologically and identified three target genes. The G protein-coupled receptor (GPR49/LGR5) is overexpressed in carcinomas (31, 32) . IMPDH2 is an enzyme involved in purine synthesis. Functional validation using siRNA-mediated knockdown against two target candidates, IMPDH2 and GPR49, resulted in moderate inhibition. siRNAmediated knockdown caused low or no inhibition in the control gene TACSTD1, which was not overexpressed in human high-risk disease. It is possible that further analysis of the candidate transcripts in cell lines with differing genomic profiles or different model systems will establish a greater therapeutic benefit.
Knockdown of CENPE showed the greatest growth inhibition in vitro. CENPE is a kinesin motor protein included in the kinetochore protein complex, whose motor activity is required for correct chromosomal alignment during metaphase. To satisfy the spindle assembly checkpoint before anaphase (33, 34) , CENPE must be simultaneously bound to both the kinetochore and spindle microtubule to prevent asymmetrical separation of sister chromatids (34) . We focused our initial studies on CENPE as knockdown showed the greatest inhibition, mitotic kinesins are druggable targets, and inhibition of mitosis is a proved cancer paradigm. The traditional microtubule-binding drugs, Vinca alkaloids and taxanes, have documented antitumor activity against a broad spectrum of malignancies, including neuroblastoma. Microtubule disruption during mitosis inhibits the mitotic spindle resulting in mitotic arrest in tumor cells, followed in some cases by cell death. CENPE's known functions are restricted to cell division, suggesting that on-target toxicity will be limited to dividing cells, theoretically providing an advantageous therapeutic index over microtubule binding agents.
GSK923295 is a potent and selective small molecule inhibitor of human CENPE with a Ki of 3.2 nmol/L. It directly inhibits microtubule-stimulated ATPase activity of the human CENPE motor domain, resulting in irreversible binding of CENPE to microtubules and mitotic arrest. GSK923295 has shown in vitro and in vivo activity against a broad spectrum of malignancies. A phase I study of GSK923295 is currently nearing completion in adults with refractory solid cancers, and early results have been promising in terms of safety (35) . The identification of CENPE in our cross-species integrative genomics study of transcriptome evolution suggests that it is also a rational target for neuroblastoma. We show that GSK923295 has significant activity against a panel of human neuroblastoma-derived cell lines in vitro and in vivo. Our findings suggest that a transgenic model recapitulating the MYCN-amplified subset of neuroblastoma can discover downstream oncogenic mediators common to tumors without MYCN amplification. Importantly, this inhibitor is relatively inactive against murine Cenpe, meaning we were unable to test the inhibitors against TH-MYCN neuroblastomas used for target discovery nor could we estimate a therapeutic index in xenograft or transgenic models. Interestingly, although the identification of CENPE included differential expression between MYCN-amplified and nonamplified human tumors, GSK023295 activity did not correlate with MYC status or CENPE expression. This suggests the presence of as yet unidentified variables important in predicting CENPE activity.
The mechanism for increased CENPE expression in neuroblastoma remains unclear. CENPE is not a known Myc target gene (http://www.myccancergene.org/index.asp). We analyzed CENPE copy number on 599 primary neuroblastoma tumors previously assayed using the Illumina HumanHap550 SNP microarray. Relative copy number loss occurred in 66 of 599 (11%) and gain in 48 of 599 (8%) of tumors. Copy number gains were mostly whole chromosome gains and were not significantly associated with CENPE overexpression (P = 0.89). This indicates that CENPE would be unlikely to have been prioritized as target using genomic data obtained at diagnosis, but it was identified through serial transcriptomic analysis of neuroblastoma progression. This suggests that serial transcriptome analysis can augment existing integrative genomic strategies.
In summary, we used serial transcriptome analysis and cross-species integration to identify molecular targets associated with tumor progression. Our gene set includes many targets with no previously established role in tumor progression and numerous candidates suitable for pathway analysis. Future follow-up studies with these genes may uncover novel biological roles in neuroblastoma oncogenesis. The focus of this study was to identify molecular targets from this gene set that have the potential to be quickly translated into therapies for high-risk neuroblastoma. This led to the preclinical evaluation of a CENPE inhibitor that is currently in an adult phase I trial. Other genes identified in this study may prove to be equally strong candidates for therapeutic targeting. Likewise, analysis of transcripts with decreasing expression may aid identification of bona fide tumor suppressor genes, which are yet to be identified in sporadic neuroblastoma. Future studies will focus on the transcriptional and posttranscriptional regulation of CENPE expression in neuroblastoma cells. In conclusion, we have provided strong preclinical rationale that serial transcriptome profiling of a spontaneous tumor model with cross-species integration can identify and prioritize novel therapeutic targets in neuroblastoma. This strategy may have utility in other tumor types and further utility in neuroblastoma for target discovery.
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